Entecavir hydrate

CAS No. 209216-23-9

Entecavir hydrate ( Baraclude; BMS 200475; SQ 34,676 )

Catalog No. M13277 CAS No. 209216-23-9

Entecavir, a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 41 In Stock
10MG 69 In Stock
25MG 104 In Stock
50MG 146 In Stock
100MG 249 In Stock
200MG 365 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Entecavir hydrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Entecavir, a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).
  • Description
    Entecavir, a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).
  • Synonyms
    Baraclude; BMS 200475; SQ 34,676
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV( HepG2 cell)
  • Research Area
    Infection
  • Indication
    ——

Chemical Information

  • CAS Number
    209216-23-9
  • Formula Weight
    295.30
  • Molecular Formula
    C12H15N5O3·H2O
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 59 mg/mL (199.8 mM)
  • SMILES
    C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2NC(=NC3=O)N.O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Levine S, et al. Antimicrob Agents ChemOthers, 2002, 46(8), 2525-2532.
molnova catalog
related products
  • GLS4

    GLS4 (Morphothiadin) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM).

  • Vebicorvir

    Vebicorvir is a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.

  • RO6889678

    RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.